FIGURE 1.

(A) Cumulative time to first response of CR/CRi with venetoclax + azacitidine (VIALE‐A; n = 190); (B) Overall survival by timing of CR/CRi in patients treated with venetoclax + azacytidine (VIALE‐A); (C) Baseline characteristics of patients achieving early or later CR/CRi with venetoclax + azacitidine (VIALE‐A). ^aOf five patients who achieved CR/CRi after study treatment discontinuation in VIALE‐A, two achieved CR/CRi within 56 days after the first dose of venetoclax and were classified as early responders, and three achieved CR/CRi ≥57 days after the first dose of venetoclax and were classified as later responders. AML, acute myeloid leukemia; CR, complete remission; CRi, complete remission with incomplete blood count recovery